Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
about
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Aspirin, cyclooxygenase inhibition and colorectal cancerA turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityNon-visible asymptomatic haematuria: a review of the guidelines from the urologist's perspective.Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adultsPreventive Aspirin and Other Antiplatelet Medication Use Among U.S. Adults Aged ≥ 40 Years: Data from the National Health and Nutrition Examination Survey, 2011-2012.Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysisA 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease.Use of antithrombotic agents among U.S. stroke survivors, 2000-2006Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic.Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians.Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirinAspirin overutilization for the primary prevention of cardiovascular disease.Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insightsAspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia.Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional health care system.Aspirin and multiple sclerosisA randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies.Aspirin use and cardiovascular events in social networks.Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention.Cardiovascular health disparities: a systematic review of health care interventions.Racial and ethnic disparities in cardiovascular medication use among older adults in the United StatesThe impact of prevention on reducing the burden of cardiovascular diseasePopulation Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart SurveyTransanal hemorrhoidal dearterialization (THD): a safe procedure for the anticoagulated patient?Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice.Individuals' responses to global CHD risk: a focus group study.Higher rate of microscopic hematuria in elderly patients who take regular doses of aspirin: Result from AHAP Study.Low-dose aspirin use and recurrent gout attacks.Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.Advancing aspirin utilization: a review of clinical and systems-based interventions.Overcoming aspirin treatment failure in diabetes.Bleeders, bleeding rates, and bleeding score.Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.Does long-term aspirin use increase the risk of neovascular age-related macular degeneration?Aspirin dosing in cardiovascular disease prevention and management: an update.Aspirin use and mortality in two contemporary U.S. cohorts.
P2860
Q22241777-0F38F40F-BB6D-4777-BDBE-B440D9A44063Q24598813-4EE7503B-75E1-490B-B85A-7B80DA27337BQ24615651-3E9C0E59-9270-4B83-90EE-B1C560212C1DQ30238815-2BAB097D-03B8-41A6-9A63-2C9D51815308Q30378668-AB222E82-2B44-4132-83C5-177D7F6C65FAQ31021374-11F053D8-A059-4F98-B80E-D2EA06FBBA44Q33584809-DF5CEEAF-822F-4BFF-8A9A-61A469D6E440Q33622632-E8B0D218-C0A5-4277-B174-2F6D5BC72B77Q33640489-32890D18-128F-4466-B5CF-35AD57D9F1BFQ33801854-BF3FBB14-8BD8-41FC-B8AA-F9E9F77C7D63Q34138140-660987A0-1F53-40FB-9368-C5EC1114AE0DQ34177563-FC75B72C-FEDD-4C55-A093-1AE1EA298023Q34657167-3FF76281-364C-4E03-9BC5-40A6A87288ADQ34663572-FF0827FC-4BDA-487C-9A33-D5D25E4289ECQ35007536-B98DAF1A-9EBE-42C1-BF13-115C4BC5ADD3Q35040366-D9755A41-0FE9-4571-B110-B4073EDABCF2Q35156722-66C0A39E-102B-40A0-9E1D-A33294A6F221Q35551012-5F3B3D39-74E8-4E34-8B18-5E03E58116DAQ35678040-2AC2B9D3-54F5-4F07-A897-B96FF8DC7508Q35712339-3D2A1AAE-68E5-4375-963C-EBCE004652FFQ35818810-B16E98D4-1D1B-4A93-9E0C-E40396FF9A8BQ36305884-FE19298E-D55F-4A7B-85D9-5611B3FAF44AQ36564342-BBFD11AA-798B-4B96-9BBB-4C4CDF27EDEEQ36632231-99F159D1-05F3-435F-A692-326C1A788202Q36650525-4E50E0CC-E607-44C3-970C-239BCE76D9B2Q36807520-D9D33126-2E3E-4EE1-96A5-014A46019628Q36836426-AF4BAB08-F33D-47FB-9E3B-F07B4EFA7CD0Q37037642-CAA9E0F6-2203-43D9-86C1-3DA191098B67Q37123231-39EE3C80-9AB1-4E50-99DE-2F8D828092B9Q37269948-4560D714-B06C-40E2-9840-04EFB286A58EQ37497192-21041D8E-8589-422C-B634-46D71ABE87ACQ37517681-804C3E8C-5D90-4B51-9AEE-945646417EB3Q37584843-E1D81B0F-3686-44B4-A5F7-98A649F81891Q37760669-86124DF0-67E3-4699-B8B4-819E825E9EDCQ38055245-0A19280D-8FEF-4B67-BDFD-3DF379C96BC9Q38117731-48A71D9A-5E35-4228-BCA4-C99438DAD2F7Q38169038-C7FF887B-322E-4FE1-BC34-9DCAB08786B7Q38189104-F2917033-5214-4AA4-BFB9-2CBA3535A21DQ38577514-AD28A734-D6DD-4BF3-9301-48C834BF66C3Q38597861-76325741-5AA1-4AEE-B986-0CE64491CDBB
P2860
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@ast
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@en
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@nl
type
label
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@ast
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@en
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@nl
prefLabel
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@ast
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@en
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@nl
P2093
P3181
P1476
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System
@en
P2093
Ali H Mokdad
Earl S Ford
Kurt J Greenland
Umed A Ajani
Wayne H Giles
P3181
P356
10.1016/J.AMEPRE.2005.08.042
P407
P577
2006-01-01T00:00:00Z